Share

EORTC hosting session at ICTR-PHE 2016 in Geneva

The EORTC will host a session at ICTR-PHE 2016, the International Conference on Translational Research in Radio-Oncology – Physics for Health in Europe, from 11:00 – 12:30 on Thursday, 18 February 2016 in Session Room 2 at the Centre International de Conférences Genève in Geneva, Switzerland.

This session will be chaired by Prof Wilfried Budach of Universitaetsklinik in Dusseldorf, Germany. The session will highlight several areas of current EORTC research where the EORTC is making significant contributions towards advancing therapies for patients with cancer.

Speakers include Dr. Damien Weber of the Paul Scherrer Institute Center for Proton Therapy in Villigen, Switzerland, who will present the EORTC radiotherapy quality assurance platform.

Following him, Dr. Sofia Rivera of the Institut Gustave Roussy in Villejuif, France, will discuss Synergy of targeted agents and radiotherapy.

Dr. Rivera will be followed by Dr. Monika Hegi of the Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland, who will talk about Lessons from translational research in EORTC Glioma trials.

Dr. Conny Vrieling of the Clinique des Grangettes in Chêne-Bougeries, Switzerland, will close the EORTC session with a talk concerning Data from the EORTC Cancer Survivorship Task Force.

Back to news list

Related News

  • First site activated in EORTC STARBURST-1, the research project on muscle-invasive bladder cancer

  • EORTC at ESMO 2026: New findings and ongoing studies

  • EORTC research presented at ESMO 2026

  • EORTC Quality of Life Group at ISOQOL 2026

  • Meet appointed ROSC Representative, EORTC Melanoma Group, Romaana Mir

  • Pink October 2026: Advancing breast cancer research, together

  • EORTC presents new results in neuro-oncology at EANO

  • In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group

  • New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults

  • New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors